Apollo makes a deal worth up to $926M; Abeona resubmits gene therapynews2024-11-12T16:07:00+00:00November 12th, 2024|Endpoints News|
Daiichi, Alteogen to work on subcutaneous Enhertu; Roche ends Nykode dealnews2024-11-08T16:08:40+00:00November 8th, 2024|Endpoints News|
Geron’s royalty deal; Minghui’s new VEGF bispecific datanews2024-11-07T15:53:28+00:00November 7th, 2024|Endpoints News|
MacroGenics pauses development of ADC; Cellectis deprioritizes CAR-Tnews2024-11-06T15:34:31+00:00November 6th, 2024|Endpoints News|
Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drugnews2024-11-05T15:28:35+00:00November 5th, 2024|Endpoints News|
Novo, Ascendis to work on monthly GLP-1; KalVista makes a royalty dealnews2024-11-04T16:20:06+00:00November 4th, 2024|Endpoints News|
FDA removes hold on three CARsgen CAR-T trials; Ono passes on itolizumabnews2024-11-01T14:38:55+00:00November 1st, 2024|Endpoints News|
Boehringer, Gubra stop work on obesity drug; Galapagos restarts CAR-T studynews2024-10-31T14:25:49+00:00October 31st, 2024|Endpoints News|
Leal Therapeutics raises $45M; SynOx adds to Series Bnews2024-10-30T14:31:13+00:00October 30th, 2024|Endpoints News|
Vera’s $300M offering; Abeona resubmits treatment for rare skin diseasenews2024-10-29T14:50:05+00:00October 29th, 2024|Endpoints News|
